---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046399"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:15:47.698901+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma Q3 net loss $1.5M; Caldolor study, DMD designations announced

## Summary
- Q3 2024 net revenue $9.1M; net loss $1.5M ($0.11 loss per share); adjusted loss $0.26M ($0.02 per share).
- Real-world study of 150k patients shows Caldolor associated with fewer adverse drug reactions vs ketorolac.
- FDA grants Orphan Drug and Rare Pediatric Disease designations for ifetroban in Duchenne Muscular Dystrophy.
- Kristalose added to Medicaid plans in VA, LA, ME; Vibativ partner in Saudi Arabia begins ordering for launch.
- Phase II MENDING trial for delirium meets primary safety endpoint; CET plans pivotal study discussion with FDA.

## SEC filing metadata
- accession: 0001628280-24-046399
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828024046399/0001628280-24-046399-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828024046399/cpix-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046399
- JSON: https://secwatch.observer/filing/0001628280-24-046399.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046399.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.